ナチュラルキラー細胞治療薬の世界市場

世界のナチュラルキラー細胞治療薬市場は、2030年までに75億米ドルに到達

世界のナチュラルキラー細胞治療薬市場は、2024年に37億米ドルと推定され、2024年から2030年にかけてCAGR 12.8%で成長し、2030年には75億米ドルに達すると予測されます。本レポートで分析したセグメントの1つであるNK細胞指向抗体治療薬は、CAGR 14.5%を記録し、分析期間終了時には53億米ドルに達すると予測されます。NK細胞治療薬セグメントの成長率は、分析期間中CAGR 9.4%と推定されます。

米国市場は9億9,650万米ドルと推定、中国はCAGR17.5％で成長予測

米国のナチュラルキラー細胞治療薬市場は、2024年に9億9,650万米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに16億米ドルの市場規模に達すると予測され、分析期間中 (2024年～2030年) のCAGRは17.5%です。その他の注目すべき地域市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ9.2％と11.5％と予測されています。欧州では、ドイツがCAGR 10.2%で成長すると予測されています。

世界のナチュラルキラー細胞治療薬市場 - 主要動向と促進要因のまとめ

ナチュラルキラー細胞治療薬が免疫腫瘍学のブレークスルーとなる理由とは？

自然リンパ球のサブセットであるナチュラルキラー（NK）細胞は、事前に感作することなくウイルス感染細胞や悪性細胞を識別して殺傷するユニークな能力により、急速に細胞免疫療法の要となっています。T細胞とは異なり、NK細胞は主要組織適合性複合体（MHC）を介した抗原提示を必要としないため、より迅速な免疫応答が可能となり、血液悪性腫瘍や固形がんを問わず幅広い治療への応用が可能です。NK細胞の細胞傷害能は、パーフォリン・グランザイム分泌、抗体依存性細胞性細胞傷害（ADCC）、サイトカイン産生などの機序によって媒介され、免疫系調節や腫瘍除去のための強力な薬剤として位置づけられています。

NK細胞を用いた治療法の開発は急速に進展しており、自己NK細胞輸注、同種NK細胞製剤、人工多能性幹細胞（iPSC）由来のNK療法、キメラ抗原受容体（CAR-NK）を組み込んだ遺伝子組み換えNK細胞などのアプローチがあります。これらの戦略は、持続性、細胞傷害性、腫瘍ホーミング、免疫抑制的腫瘍微小環境に対する抵抗性を高めることを目的としています。チェックポイント阻害剤ががんの一部で耐性に直面する中、NKベースの治療法は免疫活性化のための代替または補完的な経路を提供し、バイオファーマのイノベーターや投資家から強い関心を集めています。

製造プラットフォームと送達技術は、NK細胞療法をどのように前進させているか？

歴史的にNK細胞療法を制限してきた中心的な課題の一つは、NK細胞拡大のスケーラビリティと実行可能性でした。しかし、最近の生体外NK細胞培養、凍結保存、フィーダー細胞システム、無血清培地などの進歩により、臨床的に実行可能なNK細胞バッチを商業規模で生産できるようになりました。労働集約的な自己由来プロセスから、健康なドナーやiPS細胞由来の既製の同種NK細胞プラットフォームへの移行は、製造経済性に革命をもたらし、コストを削減し、世界のアクセスを可能にしています。

CAR-NK療法は、CAR-T療法に比べてサイトカイン放出症候群（CRS）や移植片対宿主病（GVHD）のリスクが低いことから有望視されています。CRISPR/Cas9やTALENなどの遺伝子編集ツールは、NK細胞の機能を強化し、生存期間を延長し、腫瘍選択性を改善するために使用されています。さらに、特に免疫浸潤が制限要因となる固形がんにおいて、NK細胞の生体内分布や腫瘍部位での滞留を改善するために、カプセル化やハイドロゲルを用いた送達システムが出現しつつあります。

さらに、NK細胞とモノクローナル抗体、IL-15スーパーアゴニスト、免疫チェックポイントモジュレーターの併用療法が、ADCCと腫瘍免疫回避抵抗性を高めるために研究されています。前臨床および初期の臨床データは、特にリンパ腫、神経膠芽腫、トリプルネガティブ乳がんモデルにおいて、相乗的な抗腫瘍効果を示唆しています。これらの進歩により、安全性、標的性、治療成績が改善されつつあります。

主要な応用分野と地域別の市場力学は？

急性骨髄性白血病（AML）、非ホジキンリンパ腫（NHL）、多発性骨髄腫などの血液がんは、主に血液や骨髄中の腫瘍細胞への注入細胞のアクセスが容易であることから、依然としてNK細胞療法の主要な応用分野です。同種NK細胞を用いたAMLの臨床試験では、耐久性のある奏効が示されており、CD19、CD22、BCMAを標的とするいくつかのCAR-NKプログラムが初期および中期段階の臨床試験を経て進行中です。

NK療法を固形がんに応用することへの関心も、細胞ホーミングレセプター、局在化送達、免疫回避の克服などの技術革新に後押しされて高まっています。メラノーマ、非小細胞肺がん（NSCLC）、神経膠芽腫、卵巣がんは、NK細胞療法がチェックポイント阻害剤や放射線との併用で評価されている主要な標的です。

米国は、強固なバイオテクノロジー・エコシステム、先進的な臨床インフラ、FDAによる細胞治療のファスト・トラック・パスウェイに支えられ、世界の開発状況をリードしています。欧州ではドイツ、英国、オランダに著名な研究クラスターがあります。アジア太平洋では、中国、韓国、日本などがNK細胞の研究開発に投資しており、地域のバイオテクノロジー企業が初期段階のイノベーターとして台頭してきています。政府資金、官民パートナーシップ、細胞・遺伝子治療製造のインフラ拡充により、より広範な世界参入が可能になっています。

世界のナチュラルキラー細胞治療薬市場の成長を促進しているものは何か？

世界のナチュラルキラー細胞治療薬市場の成長は、がん罹患率の上昇、従来の免疫療法の限界、細胞増殖および遺伝子編集技術におけるブレークスルーなど、いくつかの要因によってもたらされています。NK細胞は、説得力のある安全性プロファイル、短い製造期間、低い毒性リスクを提供し、単独療法と併用療法の両方にとって魅力的な治療法となります。

自家、同種、CAR-NKの各プラットフォームにおけるパイプラインの拡充は、血液がんや固形がんにおける有望な臨床成績と相まって、戦略的提携やライセンシング契約を促進しつつあります。規制当局はNK細胞療法に迅速な審査メカニズムを提供し、より迅速な試験デザインと商業的発売を促進しています。さらに、商業グレードのGMP準拠の製造フレームワークの出現により、製品の一貫性と拡張性が向上しています。

細胞療法という選択肢に対する患者や医師の認識、償還制度の改善、免疫腫瘍学におけるベンチャーキャピタルの増加は、主要地域全体の需要を強化しています。NK細胞療法が後期臨床試験に進み、市場承認を得るにつれて、標準的ながん治療プロトコールへの統合が市場の急激な普及を促進すると予想されます。

セグメント

治療薬別（NK細胞指向性抗体治療薬、NK細胞治療薬）；用途別（免疫増殖性疾患用途、消化器疾患用途、がん用途、その他用途）；エンドユーザー別（病院エンドユーザー、研究センター・研究所エンドユーザー、その他エンドユーザー）

分析対象企業の例

• Affimed N.V.
• AvenCell Therapeutics
• Bristol Myers Squibb
• Caribou Biosciences
• Celularity Inc
• Century Therapeutics
• CytoImmune Therapeutics
• Cytovia Therapeutics
• Dragonfly Therapeutics
• Fate Therapeutics
• Gilead Sciences
• GT Biopharma
• Innate Pharma
• Kiadis Pharma
• Nkarta Therapeutics
• ONK Therapeutics
• Sanofi
• Shoreline Biosciences
• Sorrento Therapeutics
• Takeda Pharmaceutical Company

AIインテグレーション

Global Industry Analystsは、有効な専門家コンテンツとAIツールによって、市場情報と競合情報を変革しています。

Global Industry Analystsは、一般的なLLMや業界別SLMのクエリに従う代わりに、ビデオ記録、ブログ、検索エンジン調査、大量の企業、製品/サービス、市場データなど、世界中の専門家から収集したコンテンツのリポジトリを構築しました。

関税影響係数

Global Industry Analystsは、本社の国、製造拠点、輸出入（完成品とOEM）に基づく企業の競争力の変化を予測しています。この複雑で多面的な市場力学は、売上原価（COGS）の増加、収益性の低下、サプライチェーンの再構築など、ミクロおよびマクロの市場力学の中でも特に競合他社に影響を与える見込みです。

目次

第1章 分析手法

第2章 エグゼクティブサマリー

• 市場概要
• 主要企業
• 市場動向と促進要因
• 世界市場の見通し

第3章 市場分析

• 米国
• カナダ
• 日本
• 中国
• 欧州
• フランス
• ドイツ
• イタリア
• 英国
• スペイン
• ロシア
• その他欧州
• アジア太平洋
• オーストラリア
• インド
• 韓国
• その他アジア太平洋
• ラテンアメリカ
• アルゼンチン
• ブラジル
• メキシコ
• その他ラテンアメリカ
• 中東
• イラン
• イスラエル
• サウジアラビア
• アラブ首長国連邦
• その他中東
• アフリカ

第4章 競合

Global Natural Killer Cells Therapeutics Market to Reach US$7.5 Billion by 2030

The global market for Natural Killer Cells Therapeutics estimated at US$3.7 Billion in the year 2024, is expected to reach US$7.5 Billion by 2030, growing at a CAGR of 12.8% over the analysis period 2024-2030. NK Cell Directed Antibodies Therapeutics, one of the segments analyzed in the report, is expected to record a 14.5% CAGR and reach US$5.3 Billion by the end of the analysis period. Growth in the NK Cell Therapies segment is estimated at 9.4% CAGR over the analysis period.

The U.S. Market is Estimated at US$996.5 Million While China is Forecast to Grow at 17.5% CAGR

The Natural Killer Cells Therapeutics market in the U.S. is estimated at US$996.5 Million in the year 2024. China, the world's second largest economy, is forecast to reach a projected market size of US$1.6 Billion by the year 2030 trailing a CAGR of 17.5% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 9.2% and 11.5% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 10.2% CAGR.

Global Natural Killer Cells Therapeutics Market - Key Trends & Drivers Summarized

What Makes Natural Killer Cell Therapeutics a Breakthrough in Immuno-Oncology?

Natural Killer (NK) cells, a subset of innate lymphoid cells, have rapidly become a cornerstone of cellular immunotherapy due to their unique ability to identify and kill virally infected and malignant cells without prior sensitization. Unlike T cells, NK cells do not require antigen presentation through major histocompatibility complexes (MHC), allowing for faster immune responses and broader therapeutic applicability across hematologic malignancies and solid tumors. Their cytotoxic potential is mediated through mechanisms such as perforin-granzyme secretion, antibody-dependent cellular cytotoxicity (ADCC), and cytokine production, positioning them as powerful agents for immune system modulation and tumor clearance.

The development of NK cell-based therapeutics is evolving rapidly, with approaches including autologous NK cell infusions, allogeneic NK cell products, induced pluripotent stem cell (iPSC)-derived NK therapies, and genetically modified NK cells engineered with chimeric antigen receptors (CAR-NK). These strategies aim to enhance persistence, cytotoxicity, tumor homing, and resistance to the immunosuppressive tumor microenvironment. As checkpoint inhibitors face resistance in a subset of cancers, NK-based therapies offer an alternative or complementary pathway for immune activation, drawing strong interest from biopharma innovators and investors.

How Are Manufacturing Platforms and Delivery Technologies Advancing NK Cell Therapy?

One of the core challenges historically limiting NK cell therapy has been the scalability and viability of NK cell expansion. However, recent advances in ex vivo NK cell culture, cryopreservation, feeder cell systems, and serum-free media have enabled the production of clinically viable NK cell batches at commercial scale. The transition from labor-intensive autologous processes to off-the-shelf allogeneic NK cell platforms derived from healthy donors or iPSCs is revolutionizing manufacturing economics, reducing costs and enabling global accessibility.

CAR-NK therapies are showing promise due to their lower risk of cytokine release syndrome (CRS) and graft-versus-host disease (GVHD) compared to CAR-T therapies. Gene-editing tools such as CRISPR/Cas9 and TALENs are being used to enhance NK cell function, prolong survival, and improve tumor selectivity. In addition, encapsulation and hydrogel-based delivery systems are emerging to improve NK cell biodistribution and retention at tumor sites, especially in solid tumors where immune infiltration is a limiting factor.

Moreover, combination therapies involving NK cells and monoclonal antibodies, IL-15 superagonists, or immune checkpoint modulators are under investigation to enhance ADCC and tumor immune evasion resistance. Preclinical and early clinical data suggest synergistic anti-tumor responses, particularly in lymphoma, glioblastoma, and triple-negative breast cancer models. These advances are collectively improving safety, targeting, and therapeutic outcomes.

What Are the Leading Application Areas and Market Dynamics Across Regions?

Hematologic cancers, such as acute myeloid leukemia (AML), non-Hodgkin lymphoma (NHL), and multiple myeloma, remain the leading application areas for NK cell therapies, largely due to easier access of infused cells to tumor cells in blood and bone marrow. Clinical trials in AML using allogeneic NK cells have shown durable responses, and several CAR-NK programs targeting CD19, CD22, and BCMA are progressing through early and mid-stage trials.

Interest in applying NK therapies to solid tumors is also intensifying, driven by innovation in cell homing receptors, localized delivery, and overcoming immune evasion. Melanoma, non-small cell lung cancer (NSCLC), glioblastoma, and ovarian cancer are key targets where NK cell therapy is being evaluated in combination with checkpoint inhibitors and radiation.

The U.S. leads the global development landscape, supported by a robust biotech ecosystem, advanced clinical infrastructure, and FDA’s fast-track pathways for cell therapies. Europe follows with prominent research clusters in Germany, the U.K., and the Netherlands. In Asia-Pacific, countries such as China, South Korea, and Japan are investing in NK cell R&D, with regional biotechs emerging as early-stage innovators. Government funding, public-private partnerships, and infrastructure expansion in cell and gene therapy manufacturing are enabling broader global participation.

What Is Fueling Growth in the Global Natural Killer Cells Therapeutics Market?

The growth in the global natural killer cells therapeutics market is driven by several factors, including rising cancer prevalence, the limitations of conventional immunotherapies, and breakthroughs in cell expansion and gene editing technologies. NK cells offer a compelling safety profile, shorter manufacturing timelines, and lower toxicity risk, making them an attractive modality for both standalone and combination therapies.

Pipeline expansion across autologous, allogeneic, and CAR-NK platforms, coupled with encouraging clinical results in hematological and solid tumors, is catalyzing strategic collaborations and licensing deals. Regulatory agencies are offering expedited review mechanisms for NK cell therapies, fostering faster trial design and commercial launches. Additionally, the emergence of commercial-grade, GMP-compliant manufacturing frameworks is improving product consistency and scalability.

Patient and physician awareness of cell therapy options, improved reimbursement frameworks, and increasing venture capital in immuno-oncology are reinforcing demand across major regions. As NK cell therapies progress into late-stage trials and gain market approvals, their integration into standard cancer care protocols is expected to drive exponential market adoption.

SCOPE OF STUDY:

The report analyzes the Natural Killer Cells Therapeutics market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:

Therapeutics (NK Cell Directed Antibodies Therapeutics, NK Cell Therapies); Application (Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application, Other Applications); End-User (Hospitals End-User, Research Centers & Institutes End-User, Other End-Users)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; Spain; Russia; and Rest of Europe); Asia-Pacific (Australia; India; South Korea; and Rest of Asia-Pacific); Latin America (Argentina; Brazil; Mexico; and Rest of Latin America); Middle East (Iran; Israel; Saudi Arabia; United Arab Emirates; and Rest of Middle East); and Africa.

Select Competitors (Total 32 Featured) -

• Affimed N.V.
• AvenCell Therapeutics
• Bristol Myers Squibb
• Caribou Biosciences
• Celularity Inc
• Century Therapeutics
• CytoImmune Therapeutics
• Cytovia Therapeutics
• Dragonfly Therapeutics
• Fate Therapeutics
• Gilead Sciences
• GT Biopharma
• Innate Pharma
• Kiadis Pharma
• Nkarta Therapeutics
• ONK Therapeutics
• Sanofi
• Shoreline Biosciences
• Sorrento Therapeutics
• Takeda Pharmaceutical Company

AI INTEGRATIONS

We're transforming market and competitive intelligence with validated expert content and AI tools.

Instead of following the general norm of querying LLMs and Industry-specific SLMs, we built repositories of content curated from domain experts worldwide including video transcripts, blogs, search engines research, and massive amounts of enterprise, product/service, and market data.

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by increasing the Cost of Goods Sold (COGS), reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

• 1. MARKET OVERVIEW
  • Influencer Market Insights
  • World Market Trajectories
  • Tariff Impact on Global Supply Chain Patterns
  • Natural Killer Cells Therapeutics - Global Key Competitors Percentage Market Share in 2025 (E)
  • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
• 2. FOCUS ON SELECT PLAYERS
• 3. MARKET TRENDS & DRIVERS
  • Breakthroughs in Allogeneic NK Cell Engineering Drive Commercialization of Natural Killer Cell Therapeutics
  • Development of Cytokine-Induced Memory-Like NK Cells Spurs Targeted Immuno-Oncology Applications
  • Surge in Solid Tumor Pipeline Activity Throws the Spotlight on Versatility of Natural Killer Cell Platforms
  • Advancements in CRISPR and CAR-NK Technology Strengthen Differentiation From T Cell Therapies
  • Expansion of GMP Manufacturing Infrastructure Supports Scalability of NK Cell Therapeutic Development
  • Investment in Off-the-Shelf NK Cell Products Accelerates Time-to-Treatment for Oncology Patients
  • Emergence of Combination Therapy Strategies Propels Integration of NK Cells With Monoclonal Antibodies
  • Collaborations With CDMO Partners Enhance Process Development for NK Cell Manufacturing
  • Rising Incidence of Hematological Malignancies Spurs First-Line Evaluation of NK Cell-Based Regimens
  • Regulatory Designations for Orphan Indications Propel Clinical Acceleration of NK Cell Therapeutics
  • Focus on Expansion and Activation Protocols Improves Potency and Persistence of NK Cell Products
  • Investor Interest in Cell-Based Immunotherapies Strengthens Pipeline Funding for NK Cell Developers
  • Exploration of iPSC-Derived NK Cell Lines Supports Batch Consistency and Cost Reduction
  • Growth in Biomarker-Driven Patient Stratification Expands Clinical Response Visibility for NK Cell Trials
  • Interest in Targeting Non-Cancer Indications Like Viral Infections Diversifies Application Landscape
  • Development of Cryopreservation Protocols for NK Cell Shipping Enhances Global Market Access
  • Engagement in Academic-Industry Consortia Accelerates Preclinical Validation of NK-Based Immunotherapies
  • Surge in Licensing Agreements and M&A Deals Propels Competitive Momentum in NK Cell Therapy Space
  • Differentiation Through Proprietary Expansion Platforms Creates Long-Term Strategic Moats
  • Growth in Personalized Immunotherapy Pipelines Positions Natural Killer Cells as Core Therapeutic Modality
• 4. GLOBAL MARKET PERSPECTIVE
  • TABLE 1: World Natural Killer Cells Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
  • TABLE 2: World Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 3: World Historic Review for Natural Killer Cells Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 4: World 16-Year Perspective for Natural Killer Cells Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets for Years 2014, 2025 & 2030
  • TABLE 5: World Recent Past, Current & Future Analysis for NK Cell Directed Antibodies Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 6: World Historic Review for NK Cell Directed Antibodies Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 7: World 16-Year Perspective for NK Cell Directed Antibodies Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 8: World Recent Past, Current & Future Analysis for NK Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 9: World Historic Review for NK Cell Therapies by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 10: World 16-Year Perspective for NK Cell Therapies by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 11: World Recent Past, Current & Future Analysis for Immunoproliferative Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 12: World Historic Review for Immunoproliferative Disorders Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 13: World 16-Year Perspective for Immunoproliferative Disorders Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 14: World Recent Past, Current & Future Analysis for Gastrointestinal Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 15: World Historic Review for Gastrointestinal Diseases Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 16: World 16-Year Perspective for Gastrointestinal Diseases Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 17: World Recent Past, Current & Future Analysis for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 18: World Historic Review for Cancer Application by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 19: World 16-Year Perspective for Cancer Application by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 20: World Recent Past, Current & Future Analysis for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 21: World Historic Review for Other Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 22: World 16-Year Perspective for Other Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 23: World Recent Past, Current & Future Analysis for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 24: World Historic Review for Hospitals End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 25: World 16-Year Perspective for Hospitals End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 26: World Recent Past, Current & Future Analysis for Research Centers & Institutes End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 27: World Historic Review for Research Centers & Institutes End-User by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 28: World 16-Year Perspective for Research Centers & Institutes End-User by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030
  • TABLE 29: World Recent Past, Current & Future Analysis for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 30: World Historic Review for Other End-Users by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 31: World 16-Year Perspective for Other End-Users by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific, Latin America, Middle East and Africa for Years 2014, 2025 & 2030

III. MARKET ANALYSIS

• UNITED STATES
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
  • TABLE 32: USA Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 33: USA Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 34: USA 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 35: USA Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 36: USA Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 37: USA 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 38: USA Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 39: USA Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 40: USA 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• CANADA
  • TABLE 41: Canada Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 42: Canada Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 43: Canada 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 44: Canada Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 45: Canada Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 46: Canada 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 47: Canada Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 48: Canada Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 49: Canada 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• JAPAN
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
  • TABLE 50: Japan Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 51: Japan Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 52: Japan 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 53: Japan Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 54: Japan Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 55: Japan 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 56: Japan Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 57: Japan Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 58: Japan 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• CHINA
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
  • TABLE 59: China Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 60: China Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 61: China 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 62: China Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 63: China Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 64: China 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 65: China Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 66: China Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 67: China 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• EUROPE
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
  • TABLE 68: Europe Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 69: Europe Historic Review for Natural Killer Cells Therapeutics by Geographic Region - France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 70: Europe 16-Year Perspective for Natural Killer Cells Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK, Spain, Russia and Rest of Europe Markets for Years 2014, 2025 & 2030
  • TABLE 71: Europe Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 72: Europe Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 73: Europe 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 74: Europe Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 75: Europe Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 76: Europe 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 77: Europe Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 78: Europe Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 79: Europe 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• FRANCE
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
  • TABLE 80: France Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 81: France Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 82: France 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 83: France Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 84: France Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 85: France 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 86: France Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 87: France Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 88: France 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• GERMANY
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
  • TABLE 89: Germany Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 90: Germany Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 91: Germany 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 92: Germany Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 93: Germany Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 94: Germany 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 95: Germany Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 96: Germany Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 97: Germany 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• ITALY
  • TABLE 98: Italy Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 99: Italy Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 100: Italy 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 101: Italy Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 102: Italy Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 103: Italy 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 104: Italy Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 105: Italy Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 106: Italy 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• UNITED KINGDOM
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
  • TABLE 107: UK Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 108: UK Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 109: UK 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 110: UK Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 111: UK Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 112: UK 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 113: UK Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 114: UK Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 115: UK 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• SPAIN
  • TABLE 116: Spain Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 117: Spain Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 118: Spain 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 119: Spain Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 120: Spain Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 121: Spain 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 122: Spain Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 123: Spain Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 124: Spain 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• RUSSIA
  • TABLE 125: Russia Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 126: Russia Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 127: Russia 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 128: Russia Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 129: Russia Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 130: Russia 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 131: Russia Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 132: Russia Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 133: Russia 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF EUROPE
  • TABLE 134: Rest of Europe Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 135: Rest of Europe Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 136: Rest of Europe 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 137: Rest of Europe Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 138: Rest of Europe Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 139: Rest of Europe 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 140: Rest of Europe Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 141: Rest of Europe Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 142: Rest of Europe 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• ASIA-PACIFIC
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
  • TABLE 143: Asia-Pacific Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 144: Asia-Pacific Historic Review for Natural Killer Cells Therapeutics by Geographic Region - Australia, India, South Korea and Rest of Asia-Pacific Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 145: Asia-Pacific 16-Year Perspective for Natural Killer Cells Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Australia, India, South Korea and Rest of Asia-Pacific Markets for Years 2014, 2025 & 2030
  • TABLE 146: Asia-Pacific Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 147: Asia-Pacific Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 148: Asia-Pacific 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 149: Asia-Pacific Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 150: Asia-Pacific Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 151: Asia-Pacific 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 152: Asia-Pacific Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 153: Asia-Pacific Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 154: Asia-Pacific 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• AUSTRALIA
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Australia for 2025 (E)
  • TABLE 155: Australia Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 156: Australia Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 157: Australia 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 158: Australia Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 159: Australia Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 160: Australia 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 161: Australia Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 162: Australia Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 163: Australia 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• INDIA
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in India for 2025 (E)
  • TABLE 164: India Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 165: India Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 166: India 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 167: India Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 168: India Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 169: India 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 170: India Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 171: India Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 172: India 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• SOUTH KOREA
  • TABLE 173: South Korea Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 174: South Korea Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 175: South Korea 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 176: South Korea Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 177: South Korea Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 178: South Korea 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 179: South Korea Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 180: South Korea Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 181: South Korea 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF ASIA-PACIFIC
  • TABLE 182: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 183: Rest of Asia-Pacific Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 184: Rest of Asia-Pacific 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 185: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 186: Rest of Asia-Pacific Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 187: Rest of Asia-Pacific 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 188: Rest of Asia-Pacific Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 189: Rest of Asia-Pacific Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 190: Rest of Asia-Pacific 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• LATIN AMERICA
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Latin America for 2025 (E)
  • TABLE 191: Latin America Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 192: Latin America Historic Review for Natural Killer Cells Therapeutics by Geographic Region - Argentina, Brazil, Mexico and Rest of Latin America Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 193: Latin America 16-Year Perspective for Natural Killer Cells Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Argentina, Brazil, Mexico and Rest of Latin America Markets for Years 2014, 2025 & 2030
  • TABLE 194: Latin America Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 195: Latin America Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 196: Latin America 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 197: Latin America Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 198: Latin America Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 199: Latin America 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 200: Latin America Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 201: Latin America Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 202: Latin America 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• ARGENTINA
  • TABLE 203: Argentina Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 204: Argentina Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 205: Argentina 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 206: Argentina Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 207: Argentina Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 208: Argentina 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 209: Argentina Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 210: Argentina Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 211: Argentina 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• BRAZIL
  • TABLE 212: Brazil Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 213: Brazil Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 214: Brazil 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 215: Brazil Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 216: Brazil Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 217: Brazil 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 218: Brazil Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 219: Brazil Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 220: Brazil 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• MEXICO
  • TABLE 221: Mexico Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 222: Mexico Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 223: Mexico 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 224: Mexico Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 225: Mexico Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 226: Mexico 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 227: Mexico Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 228: Mexico Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 229: Mexico 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF LATIN AMERICA
  • TABLE 230: Rest of Latin America Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 231: Rest of Latin America Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 232: Rest of Latin America 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 233: Rest of Latin America Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 234: Rest of Latin America Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 235: Rest of Latin America 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 236: Rest of Latin America Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 237: Rest of Latin America Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 238: Rest of Latin America 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• MIDDLE EAST
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Middle East for 2025 (E)
  • TABLE 239: Middle East Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
  • TABLE 240: Middle East Historic Review for Natural Killer Cells Therapeutics by Geographic Region - Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 241: Middle East 16-Year Perspective for Natural Killer Cells Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for Iran, Israel, Saudi Arabia, UAE and Rest of Middle East Markets for Years 2014, 2025 & 2030
  • TABLE 242: Middle East Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 243: Middle East Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 244: Middle East 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 245: Middle East Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 246: Middle East Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 247: Middle East 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 248: Middle East Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 249: Middle East Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 250: Middle East 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• IRAN
  • TABLE 251: Iran Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 252: Iran Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 253: Iran 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 254: Iran Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 255: Iran Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 256: Iran 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 257: Iran Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 258: Iran Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 259: Iran 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• ISRAEL
  • TABLE 260: Israel Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 261: Israel Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 262: Israel 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 263: Israel Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 264: Israel Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 265: Israel 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 266: Israel Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 267: Israel Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 268: Israel 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• SAUDI ARABIA
  • TABLE 269: Saudi Arabia Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 270: Saudi Arabia Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 271: Saudi Arabia 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 272: Saudi Arabia Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 273: Saudi Arabia Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 274: Saudi Arabia 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 275: Saudi Arabia Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 276: Saudi Arabia Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 277: Saudi Arabia 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• UNITED ARAB EMIRATES
  • TABLE 278: UAE Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 279: UAE Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 280: UAE 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 281: UAE Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 282: UAE Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 283: UAE 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 284: UAE Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 285: UAE Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 286: UAE 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• REST OF MIDDLE EAST
  • TABLE 287: Rest of Middle East Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 288: Rest of Middle East Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 289: Rest of Middle East 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 290: Rest of Middle East Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 291: Rest of Middle East Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 292: Rest of Middle East 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 293: Rest of Middle East Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 294: Rest of Middle East Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 295: Rest of Middle East 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030
• AFRICA
  • Natural Killer Cells Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Africa for 2025 (E)
  • TABLE 296: Africa Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 297: Africa Historic Review for Natural Killer Cells Therapeutics by Therapeutics - NK Cell Directed Antibodies Therapeutics and NK Cell Therapies Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 298: Africa 16-Year Perspective for Natural Killer Cells Therapeutics by Therapeutics - Percentage Breakdown of Value Sales for NK Cell Directed Antibodies Therapeutics and NK Cell Therapies for the Years 2014, 2025 & 2030
  • TABLE 299: Africa Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 300: Africa Historic Review for Natural Killer Cells Therapeutics by Application - Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 301: Africa 16-Year Perspective for Natural Killer Cells Therapeutics by Application - Percentage Breakdown of Value Sales for Immunoproliferative Disorders Application, Gastrointestinal Diseases Application, Cancer Application and Other Applications for the Years 2014, 2025 & 2030
  • TABLE 302: Africa Recent Past, Current & Future Analysis for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
  • TABLE 303: Africa Historic Review for Natural Killer Cells Therapeutics by End-user - Hospitals End-User, Research Centers & Institutes End-User and Other End-Users Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2023 and % CAGR
  • TABLE 304: Africa 16-Year Perspective for Natural Killer Cells Therapeutics by End-user - Percentage Breakdown of Value Sales for Hospitals End-User, Research Centers & Institutes End-User and Other End-Users for the Years 2014, 2025 & 2030

IV. COMPETITION